Christine Murray Net Worth

The estimated Net Worth of Christine Murray is at least $375 ezer dollars as of 29 December 2022. Ms. Murray owns over 5,000 units of Eiger BioPharmaceuticals Inc stock worth over $18,975 and over the last 6 years she sold EIGR stock worth over $6,100. In addition, she makes $350,174 as Independent Director at Eiger BioPharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Murray EIGR stock SEC Form 4 insiders trading

Christine has made over 1 trades of the Eiger BioPharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 5,000 units of EIGR stock worth $6,100 on 29 December 2022.

The largest trade she's ever made was selling 5,000 units of Eiger BioPharmaceuticals Inc stock on 29 December 2022 worth over $6,100. On average, Christine trades about 714 units every 0 days since 2019. As of 29 December 2022 she still owns at least 11,000 units of Eiger BioPharmaceuticals Inc stock.

You can see the complete history of Ms. Murray stock trades at the bottom of the page.

Christine Murray biography

Christine Murray serves as Independent Director of the Company. She is currently Senior Vice President of Global Regulatory Affairs at Ultragenyx Pharmaceutical, Inc., developing treatments for rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Prior to joining Ultragenyx, Ms. Murray was Vice President of Regulatory Affairs at Raptor Pharmaceuticals, a company that developed products for serious, ultra-rare diseases. Raptor was acquired by Horizon Pharma plc for approximately $800 million in 2017. Prior to that, she held positions of increasing responsibility at a number of biopharma companies, including Achaogen, Inc., Alexza Pharmaceuticals, Inc., and Gilead Sciences, Inc., in Regulatory Affairs and Quality Assurance. Ms. Murray holds a BS in Biochemistry from Liverpool University, UK, an MS in Clinical Biochemistry from the University of Newcastle-upon-Tyne, UK, and a Certification in Regulatory Affairs from the University of California Santa CruzExtension.

What is the salary of Christine Murray?

As the Independent Director of Eiger BioPharmaceuticals Inc, the total compensation of Christine Murray at Eiger BioPharmaceuticals Inc is $350,174. There are 9 executives at Eiger BioPharmaceuticals Inc getting paid more, with David Cory having the highest compensation of $2,871,850.

How old is Christine Murray?

Christine Murray is 59, she's been the Independent Director of Eiger BioPharmaceuticals Inc since 2019. There are 4 older and 14 younger executives at Eiger BioPharmaceuticals Inc. The oldest executive at Eiger BioPharmaceuticals Inc is Dr. Colin Hislop, 63, who is the Sr. VP of Clinical & Devel. Operations.

What's Christine Murray's mailing address?

Christine's mailing address filed with the SEC is C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO, CA, 94306.

Insiders trading at Eiger BioPharmaceuticals Inc

Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman és Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.

What does Eiger BioPharmaceuticals Inc do?

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.

Complete history of Ms. Murray stock trades at Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc executives and stock owners

Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Cory,
  President, Chief Executive Officer, Director
• David Apelian,
  Director
• Stephana Patton,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Sriram Ryali,
  Chief Financial Officer
• David A. Cory M.B.A., R.Ph., R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• James Shaffer,
  Chief Business Officer
• David A. Cory R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• Eldon C. Mayer III, M.B.A.,
  Exec. VP & Chief Commercial Officer
• Sriram Ryali M.B.A.,
  Chief Financial Officer
• Christine Murray,
  Independent Director
• Thomas Dietz,
  Independent Chairman of the Board
• Amit Sachdev,
  Independent Director
• Evan Loh,
  Independent Director
• Eldon Mayer,
  Executive Vice President, Chief Commercial Officer
• Jeffrey Glenn,
  Independent Director
• Dr. Evan Loh,
  CEO of Paratek Pharmaceuticals & Director
• Dr. Jeffrey S. Glenn,
  Founder, Scientific Advisor & Independent Director
• Dr. Stephana E. Patton J.D., Ph.D.,
  Consultant
• Erik Atkisson,
  Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Dr. Colin Hislop,
  Sr. VP of Clinical & Devel. Operations
• Rich Franco M.B.A.,
  Sr. VP & Progeria Program Lead
• Dr. Ingrid C. Choong,
  Sr. VP of Clinical Devel.
• Charles Bramlage,
  Director
• Edgar Engleman,
  Director
• Joanne Quan,
  Chief Medical Officer
• Eduardo Bruno Martins,
  SVP, Liver and Infectious Dise
• Ventures Vi, Llc Vivo Ventu...,
  
• James H Welch,
  Chief Financial Officer
• Nina S Kjellson,
  Director
• Kim Sablich,
  
• Partners X Lp Inter West Ma...,
  
• Ingrid Choong,
  Chief Business Officer
• Erik Atkisson,
  GC & Chief Compliance Officer
• Lisa Kelly Croswell,
  
• James Vollins,
  General Counsel
• Leen Kawas,
  
• Richard A Kayne,